Drupal.behaviors.print = function(context) {window.print();window.close();}>
Qiagen Completes SAB Buy; Added to Nasdaq-100
December 14, 2009
Qiagen Completes SAB Buy; Added to Nasdaq-100
By a GenomeWeb staff reporter
Qiagen expects the $90 million deal to complement its earlier purchase of DxS.
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Qiagen Bets SABiosciences' Pathway-Focused PCR Panels Will Help Develop Companion Dxs
November 17, 2009 / PCR Insider
Qiagen's Alacris Investment Provides Biomarker Pipeline for PCR-Based MDx Assay Panels
January 13, 2011 / PCR Insider
Qiagen Details Role of Recent Acquisitions, Agreements in Molecular Dx Business
February 11, 2010 / PCR Insider
Qiagen Closes $90M Purchase of SABiosciences, Promises 'Quick and Smooth' Integration
December 17, 2009 / PCR Insider
Qiagen Acquires SABiosciences for $90M
November 10, 2009 / GenomeWeb Daily News